Detalhe da pesquisa
1.
Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.
Future Oncol
; 18(19): 2415-2431, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583358
2.
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Am J Hematol
; 96(4): 428-435, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33421178
3.
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Br J Haematol
; 178(4): 547-560, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28466536
4.
Multiple myeloma, version 1.2013.
J Natl Compr Canc Netw
; 11(1): 11-7, 2013 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23307977
5.
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
J Natl Compr Canc Netw
; 10(10): 1211-9, 2012 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23054875
6.
The challenge of cross-trial comparisons using limited data.
Haematologica
; 99(8): e145-6, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25082787
7.
Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors.
J Control Release
; 306: 149-164, 2019 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31121280
8.
Multiple myeloma.
J Natl Compr Canc Netw
; 9(10): 1146-83, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21975914
9.
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.
Clin Cancer Res
; 22(23): 5688-5695, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27287072
10.
The role of hematopoietic stem cell transplant in follicular lymphoma.
J Natl Compr Canc Netw
; 8(3): 337-44; quiz 345, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20202463